US equities |
MU $1,097.39 ▲+0.00% NVDA $230.86 ▲+0.00% SNDK $1,787.69 ▲+0.00% STX $945.57 ▲+0.00% WDC $462.56 ▲+0.00% NKE $35.15 ▲+0.00% AMD $615.73 ▲+0.00% INTC $120.00 ▲+0.00%
FinancialContent

Chemomab Therapeutics Ltd. - American Depositary Shares (NQ:CMMB)

1.300 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Chemomab Therapeutics Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
From Chemomab Therapeutics Ltd.
Via GlobeNewswire
News headline image
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
From Chemomab Therapeutics Ltd.
Via GlobeNewswire
On Thursday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
From Chemomab Therapeutics Ltd.
Via GlobeNewswire
News headline image
11 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million. Liminatus Pharma... 
Via Benzinga
News headline image
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
From Chemomab Therapeutics Ltd.
Via GlobeNewswire
News headline image
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
From Chemomab Therapeutics Ltd.
Via GlobeNewswire
News headline image
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Chemomab Therapeutics Ltd.
Via GlobeNewswire
News headline image
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
From Chemomab Therapeutics Ltd.
Via GlobeNewswire
News headline image
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
From Chemomab Therapeutics Ltd.
Via GlobeNewswire
News headline image
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Announces New Medical and Clinical Appointments
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease ↗
Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers. 
Via Benzinga
News headline image
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >